John E. Crawford
Director/Miembro de la Junta en The University of Chicago Cancer Research Foundation .
Perfil
John E.
Crawford has been Chief Financial Officer of Phenomix Corp.
since October 2007.
Prior to joining Phenomix, Mr. Crawford served as Chief Financial Officer of NovaCardia, Inc. from January 2007 to September 2007.
He was a Director of Lipid Sciences, Inc. until October 2, 2008.
From May 2006 to December 2006, Mr. Crawford served as Chief Financial Officer of Cabrellis Pharmaceutical Corporation.
From January 2006 to May 2006, he served as Chief Financial Officer of Conforma Therapeutics Corporation.
From 1997 to December 2005, Mr. Crawford was a Consultant to life sciences and technology firms.
He was Founding President of Corvas International, Inc. and held various positions from 1987 to 1999, including Chief Financial Officer.
From 1981 to 1987, Mr. Crawford served as Vice President of International Genetic Engineering, Inc. He received an MBA from the University of Chicago and a BS in Mathematical Sciences from Stanford University.
Cargos activos de John E. Crawford
Empresas | Cargo | Inicio |
---|---|---|
The University of Chicago Cancer Research Foundation | Director/Miembro de la Junta | 11/03/2011 |
Antiguos cargos conocidos de John E. Crawford.
Empresas | Cargo | Fin |
---|---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Director Financiero/CFO | 28/10/2010 |
Lipid Sciences, Inc.
Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | Director/Miembro de la Junta | 02/10/2008 |
NovaCardia, Inc.
NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Director Financiero/CFO | 01/09/2007 |
Cabrellis Pharmaceuticals Corp.
Cabrellis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ. | Director Financiero/CFO | 01/12/2006 |
Conforma Therapeutics Corp.
Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Director Financiero/CFO | 01/05/2006 |
Formación de John E. Crawford.
Stanford University | Undergraduate Degree |
The University of Chicago | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 11 |
---|---|
Conforma Therapeutics Corp.
Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Health Technology |
Lipid Sciences, Inc.
Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | Commercial Services |
Cabrellis Pharmaceuticals Corp.
Cabrellis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ. | Health Technology |
NovaCardia, Inc.
NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Health Technology |
Archimedes Technology Group Holdings LLC
Archimedes Technology Group Holdings LLC Medical SpecialtiesHealth Technology Archimedes Technology Group Holdings LLC researches and develops medical instruments such as plasma ion separation systems. The firm provides products such as environmental research laboratory, measuring, observing, and testing equipment. It serves the medical, semiconductor, and nuclear power industries. The company was founded in 1998 and is located in San Diego, CA. | Health Technology |
Genetic Engineering, Inc.
Genetic Engineering, Inc. Agricultural Commodities/MillingProcess Industries Part of Healthier Choices Management Corp., Genetic Engineering, Inc. is a biotechnology company that specializes in bovine genetics. The company is based in Denver, CO. Genetic Engineering was acquired by Miller Diversified Corp. on May 18, 1992. | Process Industries |
Corvas International, Inc. | Health Technology |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
International Genetic Engineering, Inc.
International Genetic Engineering, Inc. Engineering & ConstructionIndustrial Services International Genetic Engineering, Inc. provides engineering services. The private company is based in Santa Monica, CA. The company was founded by Gary L. Wilcox. | Industrial Services |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Health Technology |
The University of Chicago Cancer Research Foundation |
- Bolsa de valores
- Insiders
- John E. Crawford